Oral Ketamine for Resistant Depression: Evidence, Protocols, and Policy Gaps

Oral Ketamine Emerges as a Potential Alternative for Resistant Depression

A November 2026 critical review (OpenAlex W7225255241) synthesizes recent clinical studies suggesting that oral ketamine could provide a safer and more tolerable option than intravenous (IV) ketamine for patients with treatment-resistant depression and suicidality. The review, which included 16 peer-reviewed studies published through April 2026, found that oral ketamine was generally associated with meaningful improvements in depressive symptoms and suicidality. These findings are particularly relevant as IV ketamine, while effective for some, presents logistical challenges and side effect profiles that limit its widespread use in outpatient psychiatric settings.

Mechanisms, Dosing Strategies, and Clinical Context

Oral ketamine, typically prepared by diluting injectable racemic ketamine in water or juice, is being explored as a practical alternative to IV administration. The review identified two main dosing strategies: fixed dosing (11 studies) and individualized dose-titration (5 studies). Both approaches showed substantial heterogeneity in patient populations, dosing regimens, treatment durations, and outcome measures. Most protocols involved repeated treatment sessions, and several studies used gradual ingestion ("sipping") rather than a single bolus, although direct pharmacokinetic comparisons are lacking.

The proposed mechanism of action is consistent with ketamine's established role as an N-methyl-D-aspartate (NMDA) receptor antagonist, which can rapidly modulate glutamatergic neurotransmission and downstream neuroplasticity. However, oral administration results in lower bioavailability and slower onset compared to IV, which may contribute to its superior tolerability profile but also raises questions about optimal dosing and therapeutic equivalence.

Policy and Research Implications: Standardization and Evidence Gaps

The review underscores a critical gap in the current evidence base: the lack of standardized treatment protocols and adequately powered randomized controlled trials (RCTs) directly comparing oral and IV ketamine. This heterogeneity not only complicates meta-analyses but also hinders regulatory and clinical decision-making. Without consensus on dosing and administration, clinicians face uncertainty about how to safely and effectively implement oral ketamine in practice.

• Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have not approved oral ketamine for depression, and off-label use is guided by limited data.
• Insurers and payers remain hesitant to cover oral ketamine therapy absent robust comparative trials and standardized protocols.
• Industry stakeholders may find opportunities in developing proprietary oral formulations and supporting pivotal RCTs, but must navigate a landscape of clinical uncertainty and regulatory caution.

A non-obvious implication surfaced in the review: the pragmatic appeal of oral ketamine for outpatient care may paradoxically increase the risk of inconsistent patient outcomes and off-label misuse, unless clear clinical pathways are established through collaborative research and policy efforts.

Risks, Unknowns, and the Need for Caution

Despite promising signals, oral ketamine therapy carries significant risks and unknowns. The review found that while tolerability may be superior to IV administration, the long-term safety profile of repeated oral dosing remains unclear. There is also insufficient evidence to determine whether oral ketamine is truly equivalent to IV in efficacy, particularly for acute suicidality where rapid onset is critical.

Potential adverse effects include dissociation, cognitive impairment, and misuse liability. The lack of pharmacokinetic data comparing "sipping" versus bolus ingestion introduces further uncertainty. Moreover, the review highlights that most studies to date are small, open-label, or lack active comparators, limiting the generalizability of their findings.

Future Directions: Toward Standardization and Rigorous Trials

The path forward for oral ketamine in resistant depression and suicidality hinges on the development of standardized protocols and the completion of high-quality RCTs. Multicenter trials with active comparators, clear dosing regimens, and long-term follow-up are essential to inform regulatory approval, payer coverage, and clinical guidelines.

For clinicians and researchers, the current state of evidence supports cautious optimism but not routine adoption. For industry and policymakers, the opportunity lies in bridging the evidence gap through investment in rigorous research and transparent reporting. As oral ketamine moves closer to mainstream consideration, the field must prioritize patient safety, data integrity, and equitable access to care.

By Dr. Alex M. Reed, MD, PhD. Reviewed by Dr. Jamie Lin, MD on 2026-11-05. Research based on primary literature and regulatory sources.